For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The IND.227: A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma has permanently trial closed.
The PR20 trial a Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]) has successfully reached the sample size of 410 participants and is now closed to further accrual.
The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence. Researchers are testing the addition of chemotherapy to ovarian function suppression plus hormonal therapy versus ovarian function suppression plus hormonal therapy alone. Both these approaches are used across North America, and it is not clear as to whether chemotherapy is needed in this population.
October is breast cancer awareness month and in recognition we have a new video interview with our CCTG Breast Cancer Patient Representative Michelle Audoin.
"The research investments in cancer clinical trials and progressive treatment options I have seen in recent years give me hope for the future. Which is why it’s important for me to bring my voice to the development of cancer clinical trials. I want to support inclusive trial enrollment, thereby improving the generalizability of results for diverse communities," says Michelle.
Joseph L. Pater, O.C. Kingston, Ontario
The HE1 clinical trial has permanently closed, the study confirmed that the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases. This trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals.
Primary Publication
MAC23 (Oral, Plenary) - https://www.redjournal.org/article/S0360-3016(24)00764-8/fulltext
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
